Sarcomatoid lung carcinomas show high levels of Programmed Death Ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

Sarcomatoid lung carcinomas show high levels of Programmed Death Ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

Highlights • PD-L1, tumor-infiltrating lymphocytes (TIL) were higher in SC than in NSCLC. • High levels of TIL constituted a factor of good prognosis. • PD-L1 expression distinguishes subpopulations within tumor-infiltrating lymphocytes (CD3+ or CD4+) with different prognosis. • This result could re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-08, Vol.98, p.51-58
Hauptverfasser: Vieira, Thibault, Antoine, Martine, Hamard, Cécile, Fallet, Vincent, Duruisseaux, Michael, Rabbe, Nathalie, Rodenas, Anita, Cadranel, Jacques, Wislez, Marie
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Biomarkers, Tumor
Cancer
Female
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Life Sciences
Lung Neoplasms - immunology
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung sarcomatoid carcinoma
Lymphocytes, Tumor-Infiltrating - immunology
Lymphocytes, Tumor-Infiltrating - metabolism
Macrophages - immunology
Macrophages - metabolism
Macrophages - pathology
Male
Middle Aged
Mutation
Neoplasm Metastasis
Neoplasm Staging
Non-small-cell lung cancer
Odds Ratio
PD-L1
Prognosis
Pulmonary/Respiratory
Tumor-Infiltrating lymphocytes
Tumor-Infiltratingmacrophages
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • PD-L1, tumor-infiltrating lymphocytes (TIL) were higher in SC than in NSCLC. • High levels of TIL constituted a factor of good prognosis. • PD-L1 expression distinguishes subpopulations within tumor-infiltrating lymphocytes (CD3+ or CD4+) with different prognosis. • This result could represent a justification for the use of PD-L1/PD-1 immunotherapy.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2016.05.013